Skip to content

A randomised, double blind, placebo-controlled, parallel group, clinical trial to assess the treatment effects of garlic tablet administered for two weeks orally in subjects with pulmonary tuberculosis.

A randomised, double blind, placebo-controlled, parallel group, clinical trial to assess the treatment effects of garlic tablet administered for two weeks orally in subjects with pulmonary tuberculosis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12609000703202
Enrollment
60
Registered
2009-08-14
Start date
2008-12-01
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

We could not find any study that has examined the use of Garlic (Allium sativum, garlick) to treat tuberculosis as add on to antituberculosis regimen or to prevent drug induced hepatitis. It has been reported byGholami et al (pharmacy practice, 2006, 4(3): 134) that Antituberculosis -induced Hepatotoxicity in our region is much higher than western countries (25.9% vs 4.5%) . The proposed study will provide scientifically valid data to date on whether garlic is effective in preventing hepatitis induced by anti tuberculosis regimen or not..

Interventions

There are 2 treatment arms: Randomised allocation to Garcin (1000mg). Dosage - 2 tablets per day will be administered orally for the first 2 weeks of the standard antituberculosis regimen.

Sponsors

Masih Daneshvari Hospital, National Research Institute of Tuberculosis and Lung Diseases (NRITLD)
Lead SponsorHospital

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used)

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

Patients newly diagnosed with smear positive pulmonary tuberculosis admitted to the hospital who receive standard treatment

Exclusion criteria

Human Immune Deficiency Virus (HIV) positives, confirmed hepatitis at baseline, patients with cirrhosis, renal failure, and known hypersensitivity to garlic, those prone to hemorrhage, and hypotension

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026